JAK2 and acquired polycythemia vera: Combination approaches have yielded encouraging signals, e.g., ruxolitinib + peginterferon alfa-2a in newly diagnosed PV yielded 60% molecular remissions with MPN10 improvements [26], and a prospective trial of Ropeg-IFNa plus JAK2 inhibition is ongoing (NCT06770842).